Mariosea Xl

Tolterodine tartrate, the active ingredient in Mariosea Xl, is an antimuscarinic (anticholinergic) presented as an oral tablet for systemic use. It is indicated for the management of overactive bladder symptoms such as urinary frequency, urgency, and urge incontinence in adult patients. The medication works by reducing involuntary detrusor muscle contractions, thereby improving bladder storage capacity.

GNH USA supplies Mariosea Xl as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across markets.

Tolterodine tartrate is used to treat conditions within the overactive bladder disease family by relaxing bladder muscle activity.

- Overactive bladder: improves bladder storage capacity and reduces urgency episodes. - Urinary frequency: decreases the number of daily voids. - Urinary urgency: lessens the sudden, compelling need to void. - Urge incontinence: reduces involuntary leakage episodes.

Tolterodine tartrate may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dry mouth: reduced salivary secretion causing throat discomfort. - Constipation: slowed gastrointestinal motility. - Blurred vision: temporary visual disturbances. - Headache: mild to moderate cranial pain. - Nausea: feeling of queasiness. - Dizziness: light‑headed sensation, especially on standing.

Serious or Rare Side Effects: - Urinary retention: difficulty emptying the bladder, may require catheterisation. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Tachycardia: rapid heart rate requiring medical evaluation. - Angle‑closure glaucoma: acute eye pain and visual loss. - Hepatic dysfunction: abnormal liver enzyme elevations. - Severe constipation leading to bowel obstruction.

Before prescribing Tolterodine tartrate, clinicians should consider several safety aspects.

- Renal impairment: dose adjustment may be required in severe kidney disease. - Hepatic impairment: monitor liver function in patients with liver disease. - Glaucoma: avoid in patients with uncontrolled narrow‑angle glaucoma. - Urinary retention: use cautiously in individuals with existing retention risk. - Elderly patients: start at the lowest effective dose and monitor for anticholinergic effects. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture and light.

Tolterodine tartrate can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase tolterodine plasma levels. - Other anticholinergic agents (e.g., antihistamines, tricyclic antidepressants): additive anticholinergic burden. - QT‑prolonging drugs (e.g., erythromycin): may increase risk of cardiac arrhythmia.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce tolterodine effectiveness. - Digoxin: potential increase in serum digoxin concentrations. - Alcohol: may enhance anticholinergic side effects such as dizziness and dry mouth.